Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 342-347

  Landrum, Lisa M ^a   Gold, Michael A ^a   Moore, Kathleen N ^a   Myers, Tashanna K N ^a   McMeekin, D S ^a   Walker, Joan L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Intraperitoneal catheters; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGISTRY; CATHETER INFECTION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTESTINE INJURY; LAPAROTOMY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; VAGINA DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CATHETERS, INDWELLING; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 38749142573     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.004     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 17 (9-1-2003) 3194-3200
3. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89 7 (4-2-1997) 480-487
4. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 26 (12-26-1996) 1950-1955
5. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 4 (2-15-2001) 1001-1007
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 1 (1-5-2006) 34-43
7. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100 1 (2006) 27-32
8. Markman M., and Walker J.L. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24 6 (2-20-2006) 988-994
9. Arts H.J., Willemse P.H., Tinga D.J., de Vries E.G., and Van Der Zee A.G. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma. Gynecol Oncol 69 1 (1998) 32-35
10. Liou W.S., Teng N.N., and Chan J.K. A modified technique for insertion of intraperitoneal port for chemotherapy. J Surg Oncol 90 4 (l6-15-2005) 247-248
11. Kirk I.R., Carrasco C.H., Lawrence D.D., Chuang V.P., Richli W.R., Charnsangavej C., et al. Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance. J Vasc Interv Radiol 4 2 (1993) 299-304
12. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., and Yuan C.C. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 72 1 (2001) 55-60
13. Polyzos A., Tsavaris N., Kosmas C., Giannikos L., Katsikas M., Kalahanis N., et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56 4 (1999) 291-296
14. Seewaldt V.L., Cain J.M., Goff B.A., Tamimi H., Greer B., and Figge D.A. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 67 2 (1997) 137-140
15. Rose P.G., and Piver M.S. Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57 2 (1995) 270-272
16. Braly P., Doroshow J., and Hoff S. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol Oncol 25 3 (1986) 319-333
17. Pfeifle C.E., Howell S.B., Markman M., and Lucas W.E. Totally implantable system for peritoneal access. J Clin Oncol 2 11 (1984) 1277-1280
18. Piccart M.J., Speyer J.L., Markman M., Bokkel Huinink W.W., Alberts D., Jenkins J., et al. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 12 3 Suppl 4 (1985) 90-96
19. Varney R.R., Goel R., vanSonnenberg E., Lucas W.E., and Casola G. Delayed erosion of intraperitoneal chemotherapy catheters into the bowel. Report of two cases. Cancer 64 3 (8-1-1989) 762-764
20. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 41 2 (1991) 101-106
21. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 81 1 (2001) 77-81
22. Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 90 3 (2003) 637-643
23. Sakuragi N., Nakajima A., Nomura E., Noro N., Yamada H., Yamamoto R., et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol Oncol 79 3 (2000) 420-423
24. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10 5 (1992) 706-717